Iterum Therapeutics plc (ITRMF) Non-Current Assets (2017 - 2025)

Iterum Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $18.8 million in Q3 2025.

• On a quarterly basis, Non-Current Assets rose 26722.86% year-over-year to $18.8 million in Q3 2025; TTM through Sep 2025 was $77.2 million, a 4228.1% increase from a year earlier, with the FY2024 full-year figure at $19.8 million, up 2887.63% from the prior year.
• Non-Current Assets was $18.8 million for Q3 2025 at Iterum Therapeutics, down from $19.1 million in the prior quarter.
• The five-year high for Non-Current Assets was $19.8 million in Q4 2024, with the low at $70000.0 in Q3 2024.
• Average Non-Current Assets over 5 years is $7.7 million, with a median of $5.8 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets plunged 94.17% in 2024, then soared 26722.86% in 2025.
• Over 5 years, Non-Current Assets stood at $8.2 million in 2021, then slumped by 46.75% to $4.4 million in 2022, then tumbled by 84.89% to $663000.0 in 2023, then surged by 2887.63% to $19.8 million in 2024, then fell by 5.21% to $18.8 million in 2025.
• The last three Non-Current Assets figures came in at $18.8 million (Q3 2025), $19.1 million (Q2 2025), and $19.5 million (Q1 2025), per Business Quant data.